| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
25,700,000 |
| Market
Cap: |
176.05(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.93 - $7.455 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 20.1 |
| Insider 3/6 Months : 20.7 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Verrica Pharmaceuticals is a dermatology therapeutics company focused on the development and commercialization of treatments for people living with skin diseases. Co.'s primary product candidate, VP-102, is a proprietary drug-device combination of its topical solution of cantharidin, a naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. Co. is initially developing VP-102 for the treatment of molluscum contagiosum, a highly contagious and primarily pediatric viral skin disease, external genital warts and common warts.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
2,060,199 |
2,260,199 |
8,757,101 |
| Total Buy Value |
$0 |
$12,503,039 |
$13,507,039 |
$27,160,283 |
| Total People Bought |
0 |
1 |
2 |
6 |
| Total Buy Transactions |
0 |
9 |
10 |
18 |
| Total Shares Sold |
0 |
137,181 |
288,608 |
288,608 |
| Total Sell Value |
$0 |
$403,821 |
$1,135,213 |
$1,135,213 |
| Total People Sold |
0 |
5 |
5 |
5 |
| Total Sell Transactions |
0 |
10 |
14 |
14 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hayes Christopher G. |
CHIEF LEGAL OFFICER |
• – – |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
163,226 |
|
- |
|
| Goldenberg Gary |
CHIEF MEDICAL OFFICER |
• – – |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
126,257 |
|
- |
|
| White Ted |
PRESIDENT AND CEO |
• • – |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
112,500 |
282,590 |
|
- |
|
| Bonaccorso Joe |
CHIEF COMMERCIAL OFFICER |
• – – |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
132,392 |
|
- |
|
| Kohler Terry |
CHIEF FINANCIAL OFFICER |
• – – |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
74,416 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-12-29 |
4 |
B |
$7.24 |
$838,204 |
I/I |
115,774 |
7,099,182 |
1.5 |
-5% |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-12-28 |
4 |
B |
$7.08 |
$892,901 |
I/I |
126,116 |
6,983,408 |
1.5 |
-4% |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-12-27 |
4 |
B |
$7.20 |
$574,027 |
I/I |
79,726 |
6,857,292 |
1.5 |
-2% |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-12-26 |
4 |
B |
$6.49 |
$354,691 |
I/I |
54,652 |
6,777,566 |
1.5 |
7% |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-12-22 |
4 |
B |
$6.67 |
$1,667,500 |
I/I |
250,000 |
6,722,914 |
1.5 |
2% |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-12-21 |
4 |
B |
$6.17 |
$1,234,000 |
I/I |
200,000 |
6,472,914 |
1.5 |
9% |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-12-19 |
4 |
B |
$5.36 |
$1,484,763 |
I/I |
277,008 |
6,272,914 |
1.5 |
26% |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-12-18 |
4 |
B |
$5.41 |
$2,471,953 |
I/I |
456,923 |
5,995,906 |
1.5 |
26% |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-12-15 |
4 |
B |
$5.97 |
$2,985,000 |
I/I |
500,000 |
5,538,983 |
1.5 |
15% |
|
| Hayes Christopher G. |
Chief Legal Officer |
• – – |
2023-11-15 |
4 |
S |
$2.97 |
$34,327 |
D/D |
(11,558) |
123,226 |
|
-78% |
|
| Kohler Terry |
Chief Financial Officer |
• – – |
2023-11-15 |
4 |
S |
$2.97 |
$28,607 |
D/D |
(9,632) |
34,416 |
|
-78% |
|
| Bonaccorso Joe |
Chief Commercial Officer |
• – – |
2023-11-15 |
4 |
S |
$2.97 |
$33,460 |
D/D |
(11,266) |
92,392 |
|
-78% |
|
| White Ted |
President and CEO |
• • – |
2023-11-15 |
4 |
S |
$2.97 |
$34,327 |
D/D |
(11,558) |
170,090 |
|
-78% |
|
| Goldenberg Gary |
Chief Medical Officer |
• – – |
2023-11-15 |
4 |
S |
$2.97 |
$9,017 |
D/D |
(3,036) |
86,257 |
|
-78% |
|
| Hayes Christopher G. |
Chief Legal Officer |
• – – |
2023-11-14 |
4 |
S |
$2.93 |
$64,873 |
D/D |
(22,141) |
134,784 |
|
-82% |
|
| Kohler Terry |
Chief Financial Officer |
• – – |
2023-11-14 |
4 |
S |
$2.93 |
$54,064 |
D/D |
(18,452) |
44,048 |
|
-82% |
|
| Bonaccorso Joe |
Chief Commercial Officer |
• – – |
2023-11-14 |
4 |
S |
$2.93 |
$63,229 |
D/D |
(21,580) |
103,658 |
|
-82% |
|
| White Ted |
President and CEO |
• • – |
2023-11-14 |
4 |
S |
$2.93 |
$64,873 |
D/D |
(22,141) |
181,648 |
|
-82% |
|
| Goldenberg Gary |
Chief Medical Officer |
• – – |
2023-11-14 |
4 |
S |
$2.93 |
$17,044 |
D/D |
(5,817) |
89,293 |
|
-82% |
|
| Kohler Terry |
Chief Financial Officer |
• – – |
2023-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
62,500 |
|
- |
|
246 Records found
|
|
Page 1 of 10 |
|
|
0.06 (0.88%) 
